Home » Stocks » STSA

Satsuma Pharmaceuticals, Inc. (STSA)

Stock Price: $5.43 USD -0.19 (-3.38%)
Updated Jun 21, 2021 11:23 AM EDT - Market open
Market Cap 177.20M
Revenue (ttm) n/a
Net Income (ttm) -46.25M
Shares Out 21.98M
EPS (ttm) -11.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $5.43
Previous Close $5.62
Change ($) -0.19
Change (%) -3.38%
Day's Open 5.59
Day's Range 5.36 - 5.61
Day's Volume 96,458
52-Week Range 3.50 - 36.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- All three dose strengths of STS101, administered with improved 2 nd -generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -

4 days ago - GlobeNewsWire

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-

1 month ago - GlobeNewsWire

Satsuma Pharmaceuticals (STSA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022

2 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will start in ...

3 months ago - Benzinga

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate i...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine ...

7 months ago - GlobeNewsWire

- Credit Suisse - 29th Annual Healthcare Conference - November 9 th -1 2 th

7 months ago - GlobeNewsWire

Satsuma Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

8 months ago - Zacks Investment Research

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

9 months ago - Zacks Investment Research

Investors are reeling from a late-stage flop for the company's only pipeline candidate.

9 months ago - The Motley Fool

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) has reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.

9 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President a...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business progress  and ...

10 months ago - GlobeNewsWire

ASCEND results expected to support STS101 NDA filing in Q4 2021

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharma...

11 months ago - GlobeNewsWire

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

1 year ago - GlobeNewsWire

More than 1,140 patients randomized and topline results expected in second half 2020 More than 1,140 patients randomized and topline results expected in second half 2020

1 year ago - GlobeNewsWire

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data  expected in second half of 2020

1 year ago - GlobeNewsWire

Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.

Other stocks mentioned: AKBA
1 year ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janos...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President a...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results deta...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma Pre...

1 year ago - GlobeNewsWire

Satsuma Pharma (NASDAQ: STSA) made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per share.

1 year ago - Benzinga

About STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
IPO Date
Sep 13, 2019
CEO
John Kollins
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
STSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for STSA stock is "Hold." The 12-month stock price forecast is 9.00, which is an increase of 65.75% from the latest price.

Price Target
$9.00
(65.75% upside)
Analyst Consensus: Hold